Compare Ascendis Pharma A/S (ASND) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Western Union Co — how do they compare? Ascendis Pharma A/S trades at $252.45 (market cap $16.67B), while Western Union Co trades at $7.08 (market cap $2.20B). The key difference: Ascendis Pharma A/S is far larger — about 7.6× Western Union Co's market cap, and Western Union Co pays a 13.33% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WU | |
|---|---|---|
Market Cap | $16.67B | $2.20B |
Sector | Health | Technology |
52-Week High | $277.18 | $10.28 |
52-Week Low | $189.74 | $6.36 |
Enterprise Value | $17.04B | $2.10B |
Dividend Yield | — | 13.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Western Union (WU) trades at $7.03, down 0.71% on the day, with a bearish technical outlook and recent earnings misses. The stock shows low valuation multiples (P/E 5.69, P/S 0.56) and strong profitability metrics (ROE 43.97%), but revenue has declined from $4.5B in 2022 to $4.05B in 2025. Recent news highlights challenges in retail money transfers and a new digital initiative with Rain.
The investment outlook is cautious due to declining revenue, earnings volatility, and bearish analyst sentiment. Opportunities exist from deep value metrics and dividend yield, but risks include competitive pressures and execution challenges in digital transformation. The consensus price target is $7.14, suggesting limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
